

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康生物科技集團有限公司*

Uni-Bio Science Group Limited

(incorporated in the Cayman Islands with limited liability)

(stock code: 690)

VOLUNTARY ANNOUNCEMENT

The Company is pleased to announce that it has obtained permission to initiate Phase I Human Clinical trial on application of rhEPO-Fc on treatment of certain types of anemia such as anemia due to kidney failure, anemia secondary to AZT treatment of AIDS, and anemia associated with cancer.

Uni-Bio Science Group Limited (the “Company”, and together with its subsidiaries, the “Group”) is pleased to announce that the application to State Food and Drug Administration (“SFDA”) for approval to conduct Phase I Human Clinical trial on the application of rhEPO-Fc in the People’s Republic of China (the “PRC”) has been granted.

Classified as a Class I prescription drugs Recombinant Human Erythropoietin-Fc (“rhEPO-Fc”) is synthetically produced by using recombinant DNA technology for use in persons with certain types of anemia such as anemia due to kidney failure, anemia secondary to AZT treatment of AIDS , and anemia associated with cancer.

Reference is also made to the Company’s voluntary announcement made on 8 July 2009 that the rhEPO-Fc project developed by the Group has joined the second batch topic presentation for the “New Key Drug Formulation” of the State’s Major Science and Technology Project under the “Eleventh Five-Year Plan”, and has also been approved, topic numbered 2009ZX09102-229.

* For identification purposes only

The implementation of the project of the Group represents a milestone in the development of autonomous intellectual property rights in field of medicine in China of Science and Technology.

By order of the Board
Uni-Bio Science Group Limited
Tong Kit Shing
Chairman

Hong Kong, 21 January, 2011

As at the date of this announcement, the executive directors of the Company are Mr TONG Kit Shing and Mr LIU Guoyao and the independent non-executive Directors are Mr ZHOU Yaoming, Mr LIN Jian, Mr. TSAO Hoi Ho, Terry, Mr. LOU Iok Kuong and Mr. LEUNG Ka Chun.